Smruthy Sivakumar, PhD, discusses results from a large-scale analysis of ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer. As genomic and precision medicine studies have historically underrepresented men of African ancestry, Sivakumar et al sought to shed light on disparities in this patient population.
The results were shared in as abstract as part of the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5003]). The study was conducted through a partnership between Foundation Medicine and the University of Miami Sylvester Comprehensive Cancer Center.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.